(Q28066776)

title

Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseases (English)

1 reference

inflammatory bowel diseases

main subject

0 references

author

Joanna Sieczkowska-Golub

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27582886%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Dorota Jarzębicka

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27582886%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Monika Meglicka

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27582886%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Grzegorz Oracz

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27582886%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Jaroslaw Kierkus

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27582886%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

J. Sieczkowska

1

1 reference

language of work or name

1 reference

September 2016

1 reference

Therapeutic Advances in Gastroenterology

published in

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27582886%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

volume

9

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27582886%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

issue

5

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27582886%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

page(s)

729-735

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27582886%20AND%20SRC:MED&resulttype=core&format=json

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

13 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984328

Acceptable changes in quality attributes of glycosylated biopharmaceuticals

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984328

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984328

Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984328

Practical Use of Infliximab Concentration Monitoring in Pediatric Crohn Disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984328

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984328

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984328

Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984328

Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984328

Infliximab "Top-Down" Strategy is Superior to "Step-Up" in Maintaining Long-Term Remission in the Treatment of Pediatric Crohn Disease.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984328

Physicochemical characterization of Remsima

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984328

Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984328

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984328

Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984328

Optimizing anti-TNF treatments in inflammatory bowel disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984328

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984328

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984328

Mucosal healing in inflammatory bowel diseases: a systematic review

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984328

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984328

Use of infliximab in the treatment of Crohn's disease in children and adolescents

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984328

Role of cytokines in the pathogenesis of inflammatory bowel disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984328

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

29 September 2017

1 reference

https://api.crossref.org/works/10.1177%2F1756283X16650155

Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X16650155

ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X16650155

Infliximab therapy in 30 patients with refractory pediatric crohn disease with and without fistulas in The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X16650155

Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn's disease and ulcerative colitis - experiences from a single center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X16650155

Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X16650155

Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X16650155

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X16650155

The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X16650155

Comparison of the pharmacokinetics and safety of three formulations of infliximab (CT-P13, EU-approved reference infliximab and the US-licensed reference infliximab) in healthy subjects: a randomized, double-blind, three-arm, parallel-group, single-

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X16650155

Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X16650155

A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984328

Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations

27 November 2018

1 reference

12 December 2020

12-month follow-up after successful infliximab therapy in pediatric crohn disease

1 reference

12 December 2020

Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH

1 reference

12 December 2020

ECCO position challenged by European drug regulators

1 reference

12 December 2020

Identifiers

DOI

10.1177/1756283X16650155

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27582886%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27582886%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

PubMed publication ID

2 references